NewAmsterdam Pharma Company N.V.
NAMS
$16.34
$0.311.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 223.37% | 78.77% | -65.24% | -90.12% | -87.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 223.37% | 78.77% | -65.24% | -90.12% | -87.56% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 223.37% | 78.77% | -65.24% | -90.12% | -87.56% |
| SG&A Expenses | 87.19% | 85.84% | 78.86% | 88.10% | 83.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.58% | 21.80% | 35.22% | 50.12% | 77.90% |
| Operating Income | 3.65% | -15.11% | -50.71% | -194.51% | -7,378.50% |
| Income Before Tax | -36.57% | -20.19% | -46.66% | -156.70% | -974.67% |
| Income Tax Expenses | -103.70% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.54% | -20.20% | -46.68% | -156.73% | -974.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.54% | -20.20% | -46.68% | -156.73% | -974.83% |
| EBIT | 3.65% | -15.11% | -50.71% | -194.51% | -7,378.50% |
| EBITDA | 3.69% | -15.09% | -50.70% | -194.59% | -7,237.15% |
| EPS Basic | -68.87% | 86.37% | 92.02% | 91.68% | 95.09% |
| Normalized Basic EPS | -49.81% | 87.53% | 92.51% | 92.41% | 95.05% |
| EPS Diluted | -68.87% | 86.39% | 92.03% | 91.70% | 95.11% |
| Normalized Diluted EPS | -49.81% | 87.53% | 92.51% | 92.42% | 95.07% |
| Average Basic Shares Outstanding | 41.72% | 81.08% | 161.30% | 249.59% | 333.19% |
| Average Diluted Shares Outstanding | 41.72% | 81.08% | 161.30% | 237.92% | 290.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |